

Association between polypharmacy and the persistence of delirium: a retrospective cohort study

Ken Kurisu

The University of Tokyo

Daisuke Miyabe

Yokohama Rosai Hospital

Yoshiko Furukawa

Yokohama Rosai Hospital

Osamu Shibayama

Yokohama Rosai Hospital

Kazuhiro Yoshiuchi (✉ kyoshiuc-tyk@umin.ac.jp)

The University of Tokyo <https://orcid.org/0000-0002-8164-4910>

Research

Keywords: classification and regression tree, delirium, polypharmacy, propensity score, receiver operating characteristic curve

Posted Date: August 25th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-46903/v3>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on October 6th, 2020. See the published version at <https://doi.org/10.1186/s13030-020-00199-3>.

Abstract

Background: Although the association between polypharmacy and the occurrence of delirium has been well studied, the influence of polypharmacy on the persistence of delirium remains unclear. We aimed to explore the effect of polypharmacy on the persistence of delirium.

Methods: This retrospective cohort study was conducted at a tertiary hospital. The medical records of patients diagnosed with delirium who were referred to the Department of Psychosomatic Medicine were reviewed. Presentation with delirium on day 3 was set as the outcome in this study. We counted the number of drugs prescribed on the date of referral, excluding general infusion fluids, nutritional or electrolytic products, and psychotropics. To define polypharmacy, we developed a classification and regression tree (CART) model and drew a receiver operating characteristic (ROC) curve. The odds ratio (OR) of polypharmacy for the persistence of delirium on day 3 was calculated using a logistic regression model with the propensity score as a covariate.

Results: We reviewed the data of 113 patients. The CART model and ROC curve indicated an optimal polypharmacy cutoff of six drugs. Polypharmacy was significantly associated with the persistence of delirium both before [OR, 3.02; 95% confidence interval (CI), 1.39–6.81; P = 0.0062] and after (OR, 3.19; 95% CI, 1.32–8.03; P = 0.011) propensity score adjustment.

Conclusion: We discovered an association between polypharmacy and worsening courses of delirium and hypothesized that polypharmacy might be a prognostic factor for delirium.

Background

Delirium is an acute psychiatric disorder but is caused by physiological or pharmacological factors. Therefore, the body-mind relationship is strongly associated with its pathology. Both psychiatric and physiological interventions are critical to their management [1].

Polypharmacy is a growing and social issue worldwide. Inappropriate prescribing practices mainly contribute to its occurrence [2,3]. It causes both physiological and psychological problems in patients with multiple morbidities [4,5].

The association between polypharmacy and the incidence of delirium has been well studied [6-10] and a guideline recommends drug reviews for delirium prevention [11]. However, the influence of polypharmacy on the persistence of delirium has yet to be examined thoroughly. One retrospective study investigated the effect of a drug review on the course of delirium treatment, but did not focus on the effect of the number of drugs [12].

Therefore, we aimed to explore the association between polypharmacy and the persistence of delirium.

Methods

Ethics consideration

The institutional review board of Yokohama Rosai Hospital approved the study (No. 31-42) and waived the requirement for informed consent owing to the retrospective design.

Medical record review

This retrospective cohort study was conducted at Yokohama Rosai Hospital, a tertiary medical center in Japan. We reviewed the medical records of patients (a) who had been suspected to have any psychiatric disorder by physicians in departments other than the Department of Psychosomatic Medicine, (b) who had been referred to the Department of Psychosomatic Medicine from March 2019 to October 2019, (c) who had been diagnosed with delirium, and (d) who had not been under continuous sedation.

The diagnoses was performed based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [13] by senior residents (post-graduate year of 3–5) initially and then supervised by a specialist certified by the Japanese Society of Psychiatric and Neurology (Y.F.).

We defined the first 24 hours from 9:00 p.m. on the referral date as day 1, and every subsequent period of the following 24 hours as day N. We reviewed the medical charts to determine whether patients had presented with delirium on day 3, which was denoted as the outcome. Day 3 was selected because a previous study suggested that an outcome evaluation on this day could be used to estimate the treatment effectiveness [14], and this outcome has been widely adopted [15,16]. Two authors (K.K. and D.M.; senior residents) reviewed the medical records independently referring to the prepared manual. The manual included (a) confirmation of the baseline (before referring) level of consciousness, (b) confirmation of the satisfaction for the diagnostic criteria of DSM-5 [13], and (c) discussion for disagreement in evaluation of each item of the diagnostic criteria. The manual was supervised by a board member of the Japanese Society of Psychosomatic Medicine (K.Y.). The reproducibility of the evaluation (before discussion for disagreement) was analyzed using the kappa statistic.

The number of drugs prescribed on the referral date was counted, excluding general infusion fluids, nutritional or electrolytic products, and psychotropic agents.

Statistical analysis

We used the t-test to compare the means of continuous variables, and Fisher's exact test or the chi-squared test to compare the proportions of categorical variables in patients with and without delirium symptoms on day 3.

We performed the following analyses to determine the cutoff for polypharmacy [17,18]. First, we developed a classification and regression tree (CART) model in which the maximum tree depth was fixed at one and the Gini index was used as the splitting metric. We considered the splitting value of the root node to be the cutoff value. We also generated a receiver operating characteristic (ROC) curve and

calculated the Youden index for each cutoff point. The cutoff that maximized the Youden index was considered the optimal cutoff value.

We calculated the odds ratio (OR) of polypharmacy for the persistence of delirium on day 3 using a logistic regression model with the propensity score as a covariate. Propensity scores were calculated using a logistic regression model based on the following variables: age, sex, the presence of 17 diseases in the updated Charlson comorbidity index (an index to predict mortality based on the presence of comorbid conditions) [19], the Karnofsky Performance Status (an index of physical performance ability) [20] score on admission, and psychotropics (five categories: antipsychotics, benzodiazepine or Z-drugs, ramelteon or suvorexant, antidepressants, and others). The Karnofsky Performance Status was used as an index of the severity of patients. Psychotropics were included because of their potential effects on delirium [1,21]. To confirm the sufficiency of the sample size, we performed a power analysis of the univariate logistic regression model.

All analyses were conducted using R version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria, 2019) with the packages 'powerMediation' (version 0.3.2), 'ROCR' (version 1.0-11), 'rpart' (version 4.1-15), and 'vcd' (version 1.4-7). A P-value < 0.05 was considered statistically significant.

Results

Eligible patients

Of the 113 reviewed patients, 64 (57%) did not have symptoms of delirium on day 3. The kappa statistic for a delirium evaluation was 0.66 (95% confidence interval [CI] = 0.53–0.80), which showed a substantial degree of reproducibility. The descriptive data are shown in Table 1. Only the Karnofsky Performance Status score differed significantly between patients with and without symptoms of delirium on day 3.

Number of drugs and persistence of delirium

The splitting value of the root node in the CART model was six, and this number also maximized the Youden index in the ROC curve (Figure 1). Therefore, we defined polypharmacy as the use of six or more drugs. Sixty-four (57%) patients in the cohort met this definition of polypharmacy.

As shown in Table 2, polypharmacy was significantly associated with the persistence of delirium on day 3 in the absence (OR, 3.02; 95% CI, 1.39–6.81; P = 0.0062) and presence of the propensity score as a covariate (OR, 3.19; 95% CI, 1.32–8.03; P = 0.011). The C-statistic of the propensity score model was 0.767. The power of the significance of polypharmacy in the univariate model was 0.808, suggesting that the sample size was sufficient for the study.

Discussion

The present study assessed the association between polypharmacy and the persistence of delirium and showed that the use of six or more drugs was associated with the persistence of delirium.

The results suggest that polypharmacy may not only induce delirium, as it is known to [6-8], but may also worsen the course of delirium treatment. As delirium occurs due to body-mind relationship and polypharmacy is a social issue, the results showed an example of the bio-psycho-social pathology [22]. The results support the claims of a previous study that reported the effectiveness of a drug review on the course of delirium treatment [12].

Additionally, the cutoff of six drugs, which was calculated based on the ROC curve and CART model, was congruent with the values reported by previous studies for the association of polypharmacy with adverse effects [5-10]. The incidence of drug–drug interactions, which is considered to be associated with delirium [23], may increase drastically when the number of drugs exceeds six.

This study had several limitations. First, as the study was conducted at a single institution, the sampling bias could exist. Second, the present study only included patients who were suspected to have psychiatric disorder by non-expert medical staff. As the rate of undetected delirium is extremely high [24], the generalizability of the results might be limited. Third, the outcome was evaluated based on a retrospective chart review, and therefore its accuracy could not be fully validated. Fourth, the outcome evaluation was based on the DSM-5 [13] and not on the structured clinical interview; therefore, it would not be robust. Fifth, although both the diagnosis and the outcome evaluation were supervised by trained specialists, senior residents mainly performed the work. Sixth, there was no precise criteria to resolve disagreement about the outcome evaluation. Seventh, the propensity score model did not include the severity of delirium (e.g., severity score measured using the Delirium Rating Scale, Revised-98), comorbid diseases that were not listed in the Charlson comorbidity index [19], or laboratory test data. Finally, the contents of the drugs were not considered in the analyses.

Conclusions

We discovered an association between polypharmacy and a worsening course of delirium in this pilot study. Therefore, we hypothesized that polypharmacy might be a prognostic factor for delirium. However, due to the limitations, further studies would be required to validate the present finding.

Declarations

Ethics approval and consent to participate: The institutional review board of Yokohama Rosai Hospital approved the study (No. 31-42) and waived the requirement for informed consent owing to the retrospective design.

Consent for publication: Not applicable.

Availability of data and methods: The datasets and source codes are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no conflicts of interest.

Funding: None.

Author contributions: All authors conceived the study concept and design. KK and DM collected the data. KK performed the statistical analyses. KY supervised the research project. All authors participated in the interpretation of the results and writing of the report and approved the final version of the manuscript.

Acknowledgments: We thank Dr. Kosuke Inoue for his helpful advice regarding the statistical analysis.

Abbreviations

DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; CART, classification and regression tree; ROC, receiver operating characteristic; OR, odds ratio; CI, confidence interval

References

1. Marcantonio ER. Delirium in hospitalized older adults. *N Engl J Med*. 2017;377:1456-1466.
2. Payne RA. The epidemiology of polypharmacy. *Clin Med (Lond)*. 2016;16:465-469.
3. Onoue H, Koyama T, Zamami Y, et al. Trends in polypharmacy in Japan: A nationwide retrospective study. *J Am Geriatr Soc*. 2018;66:2267-2273.
4. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. *Am Fam Physician*. 2013;87:331-336.
5. Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. *Geriatr Gerontol Int*. 2012;12:761-762.
6. Hein C, Forgues A, Piau A, Sommet A, Vellas B, Nourhashemi F. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. *J Am Med Dir Assoc*. 2014;15:850.e11-15.
7. Hosoya R, Sato Y, Ishida E, et al. Association between delirium and prehospitalization medication in poststroke patients. *J Stroke Cerebrovasc Dis*. 2018;27:1914-1920.
8. Ranhoff AH, Rozzini R, Sabatini T, Cassinadri A, Boffelli S, Trabucchi M. Delirium in a sub-intensive care unit for the elderly: occurrence and risk factors. *Aging Clin Exp Res*. 2006;18:440-445.
9. Juliebø V, Bjørø K, Krogseth M, Skovlund E, Ranhoff AH, Wyller TB. Risk factors for preoperative and postoperative delirium in elderly patients with hip fracture. *J Am Geriatr Soc*. 2009;57:1354-1361.
10. Moorey HC, Zaidman S, Jackson TA. Delirium is not associated with anticholinergic burden or polypharmacy in older patients on admission to an acute hospital: an observational case control study. *BMC Geriatr*. 2016;16:162.

11. O'Mahony R, Murthy L, Akunne A, Young J, Guideline Development Group. Synopsis of the National Institute for Health and Clinical Excellence guideline for prevention of delirium. *Ann Intern Med.* 2011;154:746-751.
12. van Velthuis EL, Zwakhalen SMG, Pijpers E, et al. Effects of a medication review on delirium in older hospitalised patients: a comparative retrospective cohort study. *Drugs Aging.* 2018;35:153-161.
13. American Psychiatric Association. *Diagnostic Statistical Manual of Mental Disorders, Fifth Edition.* Washington, DC: Am Psychiatric Association Publishing; 2013.
14. Tahir TA, Eeles E, Karapareddy V, et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. *J Psychosom Res.* 2010;69:485-490.
15. Elsayem A, Bush SH, Munsell MF, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. *J Pain Symptom Manage.* 2010;40:774-782.
16. Matsuda Y, Maeda I, Morita T, et al. Reversibility of delirium in Ill-hospitalized cancer patients: Does underlying etiology matter? *Cancer Med.* 2020;9:19-26.
17. Zhang X, Wang Y, Li C, et al. The prognostic value of tumor length to resectable esophageal squamous cell carcinoma: a retrospective study. 2017;5:e2943.
18. Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. *Cancer.* 2017;123:4391-4402.
19. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol.* 2011;173:676-682.
20. Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. *BMC Med Inform Decis Mak.* 2013;13:72.
21. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. *Am J Epidemiol.* 2006;163:1149–1156.
22. Engel GL. The need for a new medical model: a challenge for biomedicine. *Science.* 1977;196:129–136.
23. Kotlinska-Lemieszek A, Klepstad P, Haugen DF. Clinically significant drug-drug interactions involving medications used for symptom control in patients with advanced malignant disease: a systematic review. *J Pain Symptom Manage.* 2019;57:989-998.e1.
24. Inouye SK, Foreman MD, Mion LC, Katz KH, Cooney Jr LM. Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. *Arch Intern Med.* 2001;161:2467-

Tables

Table 1. Patient characteristics (N=113)

	Delirium (n=49)	No delirium (n=64)	P-value
Age (years), mean (SD)	80.76 (11.90)	81.81 (8.25)	0.60‡
Male sex, n (%)	28 (57)	34 (53)	0.81*
Charlson comorbidity index, mean (SD)	3.14 (2.02)	2.92 (2.35)	0.59‡
Karnofsky Performance Status, mean (SD)	39.59 (20.61)	48.44 (25.02)	0.04‡
Number of drugs, mean (SD)	7.04 (3.26)	6.14 (3.95)	0.19‡
Number of drugs with psychotropics, mean (SD)	10.02 (3.78)	8.66 (4.11)	0.07‡
Psychotropics use, n (%)			
Antipsychotics	33 (67)	39 (61)	0.61*
Benzodiazepine or Z-drugs	12 (24)	13 (20)	0.76*
Ramelteon or suvorexant	41 (84)	55 (86)	0.95*
Antidepressant	3 (6)	2 (3)	0.65†
Other drugs	19 (39)	18 (28)	0.32*

*, Chi-squared test; †, Fisher's exact test; ‡, Student's *t*-test.

Other drugs included anti-dementia drugs, valproic acid, Yokukansan.

Table 2. Odds ratios of polypharmacy for the persistence of delirium on day 3

	OR	95% CI	P-value
Without propensity score	3.02	1.39–6.81	0.0062
With propensity score as a covariate	3.19	1.32–8.03	0.011

OR, odds ratio; CI, confidence interval

Figures

